Clinical Trial Update: ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla [Phase 4]

View source ↗

Summary

Phase 4 trial update of HIV-1 infected, antiretroviral-experienced subjects switching to Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV Infections | Phase 4 | Status: COMPLETED